Electronic Supporting Information

Synthesis of 1,2-Oxaborole *via* Base-Mediated Borylation of Propynols

Sumit Ghosh,^a Sudip Laru,^a Mukta Singsardar,^a and Alakananda Hajra*^a

^aDepartment of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India

Email: alakananda.hajra@visva-bharati.ac.in

Table of Contents

Sl. No.	Topics	Page No.
1	General information	S3
2	Experimental procedures	S4
3	Gram-scale synthesis of 3b	S4-S5
4	Structure determination (X-ray crystallographic data for 3j)	S5–S8
5	Physical data of the compounds 3a-3z	S9–S21
6	References	S22
7	NMR spectra [1 H, 13 C{ 1 H}, and 19 F] of synthesized products	S23–S79

1. General information:

All reagents were purchased from commercial sources and used without further purification. ¹H NMR spectra were determined on 400 MHz spectrometer as solutions in CDCl₃ or DMSO- d_6 . Chemical shifts were expressed in parts per million (δ) and the signals were reported as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet), q (quartet), and coupling constants (J) were given in Hz. ${}^{13}C{}^{1}H$ NMR spectra were recorded at 100 MHz in CDCl₃ or DMSO- d_6 solution. Chemical shifts were referenced to CDCl₃ ($\delta =$ 7.26 for ¹H and $\delta = 77.16$ for ¹³C{¹H} NMR) or DMSO- d_6 (¹H, $\delta = 2.50$ ppm). as internal standard. TLC was done on silica gel-coated glass slide. All solvents were dried and distilled before use. Commercially available solvents were freshly distilled before the reaction. All reactions involving moisture-sensitive reactants were executed using oven-dried glassware. High-resolution mass spectra (HRMS) were collected using electrospray ionization (ESI) on a time-of-flight (TOF) mass spectrometer. The SCXRD-BRUKER D8QUEST collected the crystallographic data for the compounds 3j and the crystal data was solved by Olex2 1.3-ac4 software. Melting points (mp.) were determined after the recrystallization of solid compounds from a solution of dichloromethane/petroleum ether (1:3). All the propargylic alcohols were prepared by this reported method.¹

2. Experimental procedures:

$R^{1} \xrightarrow{R^{2}}_{OH} + \xrightarrow{R^{3}}_{2} \xrightarrow{Cs_{2}CO_{3} (1 \text{ equiv.})}_{DMF} \xrightarrow{R^{1}}_{HO} \xrightarrow{B - 0}_{HO} \xrightarrow{R^{2}}_{R^{2}} \xrightarrow{R^{3}}_{R^{3}}$

2.1. Typical experimental procedure for the synthesized compounds 3a-3z:

Propargylic alcohols 1 (0.2 mmol, 1 equiv.), B_2pin_2 2 (0.2 mmol, 1 equiv., 50.8 mg) and Cs_2CO_3 (0.2 mmol, 1 equiv., 65.2 mg) were loaded in an oven-dried reaction tube which was subjected to flushing with nitrogen three times. Then, DMF (2.0 mL) was added to the mixture *via* syringe, and the reaction mixture was stirred at 50 °C for 24 h. After completion of the reaction (TLC), the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure products **3a-3z**.

3. Gram-scale synthesis of 3b:



1,1-diphenyl-3-(*p*-tolyl)prop-2-yn-1-ol (**1b**, 3 mmol, 1.0 equiv., 895.15 mg), B_2pin_2 (**2**, 3 mmol, 1.0 equiv., 761.82 mg) and Cs_2CO_3 (3 mmol, 1.0 equiv., 977.46 mg) were loaded in an oven-dried 25 mL round bottom flask (RB) which was subjected to flushing with nitrogen for

three times. Then, DMF (12 mL) was added to the mixture *via* syringe, and the reaction mixture was stirred at 50 °C for 24 h under N₂ atmosphere. After completion of the reaction (TLC), the reaction mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure product **3b** (1.071 g, 79%) as a yellow solid.

4. Structure determination (X-ray crystallographic data for 3j):

The White crystal of **3j** was obtained by crystallization from a solution in dichloromethane/petroleum ether after purification by column chromatography. Chemical formula: $C_{27}H_{27}B_2ClO_4$. This data was collected on a RIGAKU SATURN724+ diffractometer using Mo–K α radiation. The data collection was carried out by standard ω -scan technique and was evaluated and reduced by using Crystal Clear-SM Expert software. Absorption correction (numerical) was applied to the collected reflections. The structures were solved by direct method using SHELXS-97 and refined by full-matrix least-squares with SHELXL-2012, refining on F2.



Wavelength	0.71073 Å

Formula	$C_{27}H_{27}B_2ClO_4$	
Crystal system	monoclinic	
Space group	P 1 21/n 1	
	a = 13.4401(4) Å	$\alpha = 90^{\circ}$
Unit cell dimensions	b = 10.9000 (3) Å	$\beta = 97.099 (3)^{\circ}$
	c = 17.4319 (5) Å	$\gamma = 90$ °
Volume	2534.15(13) Å ³	
Z	4	
R-factor (%)	7.73	

The crystallographic data have been deposited with the Cambridge Crystallographic Data Centre as a supplementary publication with a CCDC reference number **CCDC 2441373**.



Fig: S2

View of ORTEP diagram for the crystal structure of the compound 3-(3-chlorophenyl)-5,5diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxaborol-2(5*H*)-ol (3j) (Thermal ellipsoid contour at 50% probability level).

Alert level B

PLAT220_ALERT_2_B NonSolvent Resd 1 C Ueq(max)/Ueq(min) Range 7.1 Ratio.

Explanation of Alert B:

This particular alert is related to the anisotropic displacement parameters (ADPs) of a nonsolvent residue. Specifically, it indicates that for residue 1 (likely a solvent or impurity molecule), the ratio of the maximum to minimum atomic displacement parameter (Ueq(max)/Ueq(min)) is unusually large 7.1 in this case. Typically, for well-ordered atoms in a crystal structure, the ratio of these parameters should not deviate significantly from 1. If the ratio is much larger, it can indicate that the atom's motion is highly anisotropic or that there is some disorder in the structure.

PLAT242_ALERT_2_B Low 'MainMol' Ueq as Compared to Neighbors of C00J Check

PLAT242_ALERT_2_B Low 'MainMol' Ueq as Compared to Neighbors of C00L Check

Explanation of Alert B:

This alert appears in crystallographic refinement reports, typically from software like **PLATON**, and highlights that the **Ueq** (which describes the thermal motion or disorder of an atom) of the **MainMol** atoms is unusually low compared to the neighboring atoms **C00J** and **C00L**.

PLAT412_ALERT_2_B Short Intra XH3 .. XHn H00G ..H00V . 1.76 Ang. x,y,z = 1_555 Check

Explanation of Alert B:

The PLAT412_ALERT_2_B is a warning from a crystallographic refinement check (typically using PLATON or similar tools) that points to a **short intra-molecular hydrogen bond** between two hydrogen atoms, H00G and H00V, with a distance of 1.76 Å, which is shorter than expected.

The alert is flagging a **hydrogen-hydrogen distance** of **1.76** Å, which is unusually short for a hydrogen bond, as typical hydrogen-hydrogen distances in molecular crystals tend to be larger. In most well-refined structures, **hydrogen-hydrogen distances** are expected to be longer than **1.76** Å.

The specific **intra XH3** .. **XHn** part of the message suggests that this involves a hydrogen atom (designated by **XH3**) interacting with another hydrogen atom (**XHn**), and the software has detected that the distance between these atoms is shorter than expected based on typical structural parameters.

5. Physical data of the compounds 3a-3z:



3,5,5-triphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxaborol-2(5H)-ol (3a): Brown yellow solid (80.7 mg, 92%); mp. 109–110 °C; R_f 0.45 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ 7.50 (d, *J* = 7.6 Hz, 2H), 7.46-7.44 (m, 3H), 7.35-7.24 (m, 10H), 1.08 (m, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 43.4, 137.5, 128.3, 128.2, 128.0, 127.9, 127.6, 127.5, 94.5, 84.1, 24.8; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₇H₂₉B₂O₄]⁺: 439.2246; Found 439.2272.



5,5-*diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(p-tolyl)-1,2-oxaborol-*2(5H)-ol (3b): Yellow solid (85.9 mg, 95%); mp. 140–141 °C; R_f 0.45 (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.46-7.41 (m, 6H), 7.34-7.28 (m, 6H), 7.14 (d, *J* = 8 Hz, 2H), 5.04 (s, 1H), 2.35 (s, 3H), 1.10 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 167.9, 143.5, 137.3, 134.5, 131.1, 128.9, 128.3, 128.0, 127.9, 127.5, 94.4, 84.1, 24.8, 21.3; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₈H₃₁B₂O₄]⁺: 453.2403; Found 453.2412.



3-(4-methoxyphenyl)-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3c): Reddish yellow solid (85.3 mg, 91%); mp. 138–139 °C; R_f 0.35 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ 7.30 (d, J = 8.8, 2H), 7.26-7.24 (m, 3H), 7.14-7.06 (m, 7H), 6.67 (d, J = 8.8, 2H), 3.61 (s, 3H), 0.90 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 159.2, 143.4, 130.0, 129.7, 128.0, 127.8, 127.7, 127.5, 113.5, 94.4, 84.0, 55.3, 24.8; HRMS (ESI–TOF) m/z: [M + Na]⁺ Calcd for [C₂₈H₃₀B₂O₅Na]⁺: 491.2172; Found 491.2162.



3-(4-hydroxyphenyl)-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3d): Brown solid (77.3 mg, 85%); mp. 156–157 °C; R_f 0.4 (PET:EtOAc
7:3); ¹H NMR (DMSO-d₆, 400 MHz): δ 9.49 (s, 1H), 9.18 (s, 1H), 7.34-7.26 (m, 12H),
6.71 (d, J = 8.4 Hz, 2H), 1.04 (s, 12H); ¹³C{¹H} NMR (DMSO-d₆, 100 MHz): δ 157.0, 144.0,
129.5, 128.3, 127.7, 127.4, 127.3, 114.7, 92.7, 83.5, 24.5; HRMS (ESI–TOF) m/z: [M + H]⁺
Calcd for [C₂₇H₂₉B₂O₅]⁺: 455.2196; Found 455.2207.



3-(4-aminophenyl)-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3e): Brown solid (77.97 mg, 86%); mp. 158–159 °C; R_f 0.4 (PET:EtOAc = 7:3); ¹H NMR (CDCl₃, 400 MHz): δ 7.43-7.41 (m, 4H), 7.36 (d, J = 8.4 Hz, 2H), 7.31-7.25 (m, 6H), 6.70 (d, J = 8.0 Hz, 2H), 1.08 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 144.7, 143.6, 129.7, 128.8, 128.1, 127.8, 127.5, 115.5, 94.3, 84.0, 24.8; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₇H₃₀B₂NO₄]⁺: 454.2355; Found 454.2362.



3-(4-fluorophenyl)-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-

oxaborol-2(5H)-ol (3f): White solid (74.9 mg, 82%); mp. 154–155 °C; R_f 0.4 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.51-7.48 (m, 2H), 7.44-7.41 (m, 4H), 7.34-7.28 (m, 6H), 7.03-6.99 (m, 2H), 5.10 (s, 1H), 1.08 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 162.5 (J_{C-F} = 245 Hz), 143.2, 133.4 (J_{C-F} = 3.0 Hz), 130.2, 130.1, 128.0, 127.9, 127.8, 127.7, 127.5, 115.1, 114.9, 114.8 (J_{C-F} = 14.0 Hz), 94.6, 84.2, 24.8; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -114.93; HRMS (ESI–TOF) m/z: [M + Na]⁺ Calcd for [C₂₇H₂₇B₂FO₄Na]⁺: 479.1972; Found 479.1982.



3-(4-chlorophenyl)-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3g): White solid (76.58 mg, 81%); mp. 180–181 °C; R_f 0.45 (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.46-7.44 (m, 2H), 7.43-7.40 (m, 4H), 7.33-7.28 (m, 8H), 4.89 (s, 1H), 1.08 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 143.1, 135.9, 133.4, 129.8, 128.2, 128.0, 127.9, 127.7, 94.6, 84.3, 24.8; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₇H₂₈B₂ClO₄]⁺: 473.1857; Found 473.1880.



1-(4-(2-hydroxy-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1,2-oxaborol-3-yl)phenyl)ethan-1-one (3h): White solid (80.67 mg, 84%); mp. 168–169 °C; R_f 0.4 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ 7.92-7.90 (m, 2H), 7.60-7.58 (m, 2H), 7.44-7.42 (m, 4H), 7.33-7.30 (m, 6H), 5.68 (s, 1H), 2.59 (s, 3H), 1.07 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 198.2, 142.9, 142.6, 135.8, 128.6, 128.2, 128.0, 127.9, 127.7, 94.7, 84.3, 26.7, 24.7; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₉H₃₁B₂O₅]⁺: 481.2352; Found 481.2362.



5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(m-tolyl)-1,2-oxaborol-2(5H)-ol (3i): Pale yellow solid (75.10 mg, 83%); mp. 119–120 °C; R_f 0.4 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.44-7.41 (m, 4H), 7.31-7.24 (m, 8H), 7.20 (t, *J* = 8.4 Hz, 1H), 7.06 (d, *J* = 7.6 Hz, 1H), 5.21 (s, 1H), 2.33 (s, 3H), 1.06 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 143.3, 137.5, 137.3, 128.8, 128.3, 128.1, 128.0, 127.9, 127.7, 127.5, 125.4, 94.5, 84.0, 24.8, 21.5; HRMS (ESI–TOF) m/z: [M + K]⁺ Calcd for [C₂₈H₃₀B₂O₄K]⁺: 491.1962; Found 491.1956.



3-(3-chlorophenyl)-5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3j): White solid (75.7 mg, 80%); mp. 152–153 °C; R_f 0.45 (PET:EtOAc = 4:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.41 (s, 1H), 7.33-7.31 (m, 4H), 7.23-7.16 (m, 7H), 7.14-7.12 (m, 2H), 5.56 (s, 1H), 0.99 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 142.9, 139.2, 133.8, 129.4, 128.2, 128.0, 127.9, 127.7, 127.4, 126.8, 94.7, 84.3, 24.8; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₇H₂₈B₂ClO₄]⁺: 473.1857; Found 473.1880.



5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(3-(trifluoromethyl)phenyl)-1,2-oxaborol-2(5H)-ol (3k): White solid (87.1 mg, 86%); mp. 148–149 °C; R_f 0.45 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ 7.82 (s, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.48-7.44 (m, 5H), 7.38-7.33 (m, 6H), 5.88 (s, 1H), 1.10 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 144.6 (J = 366 Hz), 138.1, 132.0, 130.7, 130.4, 130.1, 129.8, 128.5, 128.0 (J = 7 Hz), 127.9, 127.8, 125.7, 125.0 (J = 3 Hz), 125.03, 124.24, 124.1 (J = 6 Hz), 123.0, 120.3, 94.9, 84.3, 24.7; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -62.27; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₈H₂₈B₂F₃O₄]⁺: 507.2120; Found 507.2143.



5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(o-tolyl)-1,2-oxaborol-

2(5H)-ol (3l): White solid (76.87 mg, 85%); mp. 111–112 °C; R_f 0.4 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.46-7.44 (m, 4H), 7.35-7.29 (m, 6H), 7.15-7.09 (m, 4H), 5.08 (s, 1H), 2.28 (s, 3H), 0.94 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 143.6, 137.9, 135.4, 129.5, 128.4, 127.9, 127.8, 127.5, 126.9, 125.2, 94.7, 83.8, 24.4, 20.5; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₈H₃₁B₂O₄]⁺: 453.2403; Found 453.2438.



5,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(thiophen-2-yl)-1,2oxaborol-2(5H)-ol (3m): Brown solid (70.18 mg, 79%); mp. 132–133 °C; R_f 0.35 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.54 (d, J = 3.6 Hz, 1H), 7.42-7.40 (m, 4H), 7.33-7.28 (m, 7H), 7.03-7.01 (m, 1H), 5.23 (s, 1H), 1.16 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 143.1, 139.6, 128.8, 128.1, 127.8, 127.6, 127.4, 126.2, 94.9, 84.3, 25.0; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for [C₂₅H₂₇B₂O₄S]⁺: 445.1811; Found 445.1820.



3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,5-di-p-tolyl-1,2-oxaborol-2(5H)ol (3n): White solid (82.98 mg, 89%); mp. 152–153 °C; R_f 0.35 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.52-7.50 (m, 2H), 7.36-7.30 (m, 6H), 7.28-7.22 (m, 1H), 7.14-7.12 (m, 4H), 5.53 (s, 1H), 2.36 (s, 6H), 1.10 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 140.4, 137.6, 137.1, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.3, 94.4, 84.0, 24.8, 21.2; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₉H₃₃B₂O₄]⁺: 467.2559; Found 467.2602.



5-methyl-5-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(p-tolyl)-1,2-oxaborol-2(5H)-ol (3o): White solid (56.28 mg, 72%); mp. 158–159 °C; R_f 0.4 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.45-7.42 (m, 2H), 7.36 (d, *J* = 8.4 Hz, 2H), 7.31-7.27 (m, 2H), 7.24-7.20 (m, 1H), 7.12 (d, *J* = 8 Hz, 2H), 4.81 (s, 1H), 2.33 (s, 3H), 1.93 (s, 3H), 1.10 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 142.3, 137.2, 134.4, 128.8, 128.4, 128.2, 127.4, 125.8, 89.7, 83.9, 26.5, 24.8, 24.5, 21.3; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₃H₂₉B₂O₄]⁺: 391.2246 Found 391.2234.



5-methyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(p-tolyl)-1,2-oxaborol-2(5H)-ol (3p): White solid (61.83 mg, 79%); mp. 168–169 °C; R_f 0.45 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.47-7.45 (m, 2H), 7.35-7.28 (m, 4H), 7.25-7.22 (m, 1H), 7.11 (d, J = 8.0 Hz, 2H), 5.31 (s, 1H), 2.31 (s, 3H), 1.93 (s, 3H), 1.12 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 139.2, 137.4, 137.0, 128.9, 128.3, 128.0, 127.3, 125.7, 89.8, 83.9, 26.6, 24.8, 24.5, 21.1; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₃H₂₉B₂O₄]⁺: 391.2246; Found 391.2255.



5-(3-bromophenyl)-5-methyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3q): White solid (68.54 mg, 75%); mp. 156–157 °C; R_f 0.4 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.51 (s, 1H), 7.35-7.33 (m, 2H), 7.29-7.25 (m, 2H), 7.20 (t, *J* = 7.2 Hz, 2H), 7.16-7.12 (m, 1H), 7.09-7.05 (m, 1H), 5.54 (s, 1H), 1.82 (s, 3H), 1.04 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 144.9, 137.0, 130.4, 129.9, 128.9, 128.3, 128.1, 127.5, 124.3, 122.4, 89.5, 84.1, 26.8, 24.9, 24.6; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₂H₂₆B₂BrO₄]⁺: 455.1195; Found 455.1230.



5-methyl-5-(naphthalen-2-yl)-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3r): White solid (67.59 mg, 79%); mp. 138–139 °C; R_f 0.4 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ 8.00 (s, 1H), 7.88-7.83 (m, 3H), 7.61-7.59 (m, 1H), 7.56-7.54 (m, 2H), 7.51-7.49 (m, 2H), 7.36 (t, *J* = 7.6 Hz, 2H), 7.31-7.27 (m, 1H), 5.95 (s, 1H), 2.14 (s, 3H), 1.11 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 139.7, 137.3, 133.2, 132.7, 128.3, 128.2, 128.09, 128.06, 127.6, 127.4, 126.0, 125.9, 124.5, 124.1, 90.0, 84.0, 26.6, 24.8, 24.4; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₆H₂₉B₂O₄]⁺: 427.2246; Found 427.2274.



5-(benzo[d][1,3]dioxol-5-yl)-5-methyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxaborol-2(5H)-ol (3s): Brown solid (62.50 mg, 74%); mp. 179–180 °C; R_f 0.4 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ ¹H NMR (CDCl₃, 400 MHz): δ 7.51-7.48 (m, 2H), 7.36-7.32 (m, 2H), 7.30-7.25 (m, 1H), 6.99-6.96 (m, 2H), 6.78-6.76 (m, 1H), 5.95-5.94 (m, 2H), 1.95 (s, 3H), 1.17 (s, 12H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 147.6, 146.8, 137.3, 136.3, 128.3, 128.0, 127.3, 119.2, 107.8, 106.8, 101.0, 89.6, 84.0, 26.7, 24.8, 24.5; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₃H₂₇B₂O₆]⁺: 421.1988; Found 421.2016.



5-(2-fluorophenyl)-5-methyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3t): Green solid (59.11 mg, 75%); mp. 148–149 °C; R_f 0.5 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.37-7.33 (m, 3H), 7.19-7.15 (m, 2H), 7.12-7.08 (m, 2H), 6.95 (t, *J* = 7.6 Hz, 1H), 6.88-6.83 (m, 1H), 5.37 (s, 1H), 1.84 (s, 3H), 1.00 (s, 6H), 0.97 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 160.9 (*J*_{C-F} = 247.0 Hz), 137.4, 129.5 (*J*_{C-F} = 9.0 Hz), 129.4, 129.3, 128.2, 128.1, 127.9, 127.3, 123.9 (*J*_{C-F} = 3.0 Hz), 116.3 (*J*_{C-F} = 23.0 Hz), 88.6, 84.1, 26.9, 26.8, 24.9, 24.6; ¹⁹F NMR (376.5 MHz, CDCl₃): δ -109.53; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₂H₂₆B₂FO₄]⁺: 395.1996; Found 395.2014.



5-methyl-3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(thiophen-2-yl)-1,2oxaborol-2(5H)-ol (3u): Brown solid (61.90 mg, 81%); mp. 130–131 °C; R_f 0.4 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.51-7.48 (m, 2H), 7.34-7.30 (m, 2H), 7.28-7.24 (m, 1H), 7.21-7.19 (m, 1H), 7.07-7.06 (m, 1H), 6.93-6.91 (m, 1H), 5.78 (s, 1H), 2.01 (s, 3H), 1.16 (s, 6H), 1.13 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 147.3, 137.0, 128.4, 128.0, 127.5, 126.6, 125.0, 124.6, 87.7, 84.0, 27.7, 24.7, 24.4; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₀H₂₅B₂O₄S]⁺: 383.1654; Found 383.1650.



3,5-diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)-1,2oxaborol-2(5H)-ol (3v): White solid (67.09 mg, 78%); mp. 182–183 °C; R_f 0.4 (PET:EtOAc = 85:15); ¹H NMR (DMSO-d₆, 400 MHz): δ 9.95 (s, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.47-7.37 (m, 6H), 7.36-7.29 (m, 3H), 1.16 (s, 6H), 1.14 (s, 6H); ¹³C{¹H} NMR (DMSO-d₆, 100 MHz): δ 152.6 (J_{C-F} = 250.0 Hz), 151.3 (J_{C-F} = 3.0 Hz), 151.2, 136.3, 134.9, 128.9, 128.4, 128.1 (J_{C-F} = 9.0 Hz), 127.8, 126.2, 125.8, 123.0, 88.8 (t, J_{C-F} = 29.0 Hz), 84.2, 24.5, 24.4; ¹⁹F NMR (376.5 MHz, DMSO-d₆): δ -74.0; **HRMS** (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₂H₂₄B₂F₃O₄]⁺: 431.1807; Found 431.1811.



3'-phenyl-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-2'H-spiro[indene-

1,5'-[1,2]oxaborol]-2'-ol (3w): White solid (55.04 mg, 71%); mp. 170–171 °C; R_f 0.4 (PET:EtOAc = 85:15); ¹H NMR (CDCl₃, 400 MHz): δ 7.56-7.53 (m, 2H), 7.35-7.30 (m, 2H), 7.28-7.22 (m, 3H), 7.17-7.15 (m, 1H), 7.14-7.09 (m, 1H), 5.19 (s, 1H), 3.27-3.19 (m, 1H), 3.10-3.03 (m, 1H), 2.88-2.80 (m, 1H), 2.33-2.27 (m, 1H), 1.02 (s, 6H), 0.97 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 144.7, 142.7, 137.3, 128.8, 128.3, 128.2, 127.4, 126.6, 124.9, 124.0, 98.2, 83.9, 37.4, 30.6, 24.5, 24.2; HRMS (ESI–TOF) m/z: [M + H]⁺ Calcd for [C₂₃H₂₇B₂O₄]⁺: 389.2090; Found 389.2115.



3-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(p-tolyl)-1,2-oxaborol-2(5H)-ol
(3x): Brown oil (55.09 mg, 73%); R_f 0.5 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ
7.57-7.55 (m, 2H), 7.35-7.31 (m, 2H), 7.28-7.24 (m, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 7.6 Hz, 2H), 5.86 (s, 1H), 2.32 (s, 3H), 1.08 (s, 6H), 1.03 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 138.0, 137.1, 135.5, 129.1, 128.4, 128.1, 127.5, 127.3, 87.0, 84.1, 24.7, 24.2,

21.3; **HRMS** (ESI–TOF) m/z: $[M + H]^+$ Calcd for $[C_{22}H_{27}B_2O_4]^+$: 377.2090; Found 377.2109.



5-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(p-tolyl)-1,2-oxaborol-2(5H)-ol (3y): Yellow solid (55.66 mg, 74%); mp. 135–136 °C; R_f 0.5 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.48 (d, J = 8.0 Hz, 2H), 7.32-7.25 (m, 5H), 7.14 (d, J = 8.0 Hz, 2H), 5.88 (s, 1H), 5.28 (s, 1H), 2.35 (s, 3H), 1.07 (s, 6H), 1.03 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 138.6, 137.4, 134.0, 128.9, 128.4, 128.3, 127.4, 87.1, 84.0, 24.7, 24.2, 21.4; HRMS (ESI–TOF) m/z: [M + K]⁺ Calcd for [C₂₂H₂₆B₂O₄K]⁺: 415.1649; Found 415.1660.



3-(2-bromo-4-chlorophenyl)-5-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2oxaborol-2(5H)-ol (3z): Yellow solid (66.70 mg, 70%); mp. 185–186 °C; R_f 0.45 (PET:EtOAc = 9:1); ¹H NMR (CDCl₃, 400 MHz): δ 7.60-7.56 (m, 3H), 7.37-7.32 (m, 2H), 7.31-7.27 (m, 1H), 7.24-7.21 (m, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 6.35 (s, 1H), 5.11 (s, 1H), 1.11 (s, 6H), 1.05 (s, 6H); ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 136.7, 136.5, 134.8, 132.5, 129.8, 128.39, 128.31, 128.0, 127.9, 125.0, 84.7, 84.3, 24.7, 24.3; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for [C₂₁H₂₃B₂BrClO₄]⁺: 475.0649; Found 475.0673.

6. References:

(1) (a) Zhu, W.-R.; Su, Q.; Deng, X.-Y.; Ouyang, Z.-L.; Weng, J.; Lu, G. Organocatalytic asymmetric cascade bicyclization: access to chiral polycyclic bisindoles from 2-indolylmethanols and propargylic alcohols. *Org. Chem. Front.* **2024**, *11* (7), 2040-2046. (b) He, W.; Zheng, W.-F.; Qian, H. Rh-Catalyzed Carbonylative Cyclization of Propargylic Alcohols with Aryl Boronic Acids. *Org. Lett.* **2024**, *26* (29), 6279-6283. (c) Yan, W.; Wang, Q.; Chen, Y.; Petersen, J. L.; Shi, X. Iron-Catalyzed C–O Bond Activation for the Synthesis of Propargyl-1,2,3-triazoles and 1,1-Bistriazoles. *Org. Lett.* **2010**, *12* (15), 3308-3311.

7. NMR spectra [¹H, ¹³C {¹H}, and ¹⁹F] of synthesized products







1







٦







,



1




























0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 ppm















Ŧ









S58









-







	PROCNO 1
$ \begin{array}{c} $	F2 - Acquisition Paramete Date
Solvent: CDCl ₃	TE 295.3 K D1 1.00000000 s TD0 1
	======= CHANNEL fl ===== SF01 376.4795333 M NUC1 19F P1 12.50 PL 20.00000000 W
	F2 - Processing parameter SI 16384 SF 376.5171850 M WDW EM SSB 0 LB 0.30 H GB 0 FC 1.00

BRÚKER \times







,





0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 ppm




.









٦

S77



.

S78

